Trials / Sponsors / Catalyst Biosciences

Catalyst Biosciences

Industry · 8 registered clinical trials.

Status	Trial	Phase	Started
Terminated	A Natural History Study to Assess the Clinical Outcomes of Patients With Complement Factor I Deficiency-Mediat Recurrent Bacterial Infection, Autoimmune Disorder	—	2021-08-31
Terminated	Screening Study to Identify Patients With Complement Factor I Deficiencies Previous Diagnosis With a Complement-mediated Disease and/or With Clinical Manifestations Reasonably Associated With Complement Factor I Deficiency	—	2021-07-21
Terminated	Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders Factor VII Deficiency, Glanzmann Thrombasthenia, Hemophilia A With Inhibitor	Phase 1 / Phase 2	2021-05-17
Terminated	Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B Hemophilia A With Inhibitor, Hemophilia B With Inhibitor	Phase 3	2021-05-04
Completed	Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia Hemophilia A, Hemophilia B, Hemophilia A With Inhibitor	Phase 1	2019-09-24
Completed	Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B Hemophilia B	Phase 2	2019-06-18
Completed	Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and Hemophilia A With Inhibitor, Hemophilia B With Inhibitor	Phase 2	2017-12-18
Completed	Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Hemophilia A	Phase 1	2011-12-01